Literature DB >> 25353652

Phosphorothioates, essential components of therapeutic oligonucleotides.

Fritz Eckstein1.   

Abstract

Phosphorothioates have found their usefulness in the general area of oligonucleotide therapeutic applications. Initially this modification was introduced into the antisense methodology because of the nuclease resistance of the phosphorothioate linkage in comparison with that of the phosphate linkage. However, as experimental data accumulated, it was detected that this chemical modification also facilitates cellular uptake and bioavailibity in vivo. Thus, today the majority of therapeutic oligonucleotides contain this modification. This review will discuss the historical development of this modification and present some of its chemical properties where they differ from those of the phosphate group. The antisense application will be discussed in the original context with cleavage of the target mRNA, but other target RNAs such as microRNAs and long noncoding RNAs will also be covered. It continues with applications where the target RNA should not be cleaved. A brief presentation of decoy oligonucleotides will be included, as well as some miscellaneous applications. Cellular uptake is a crucial step for oligonucleotides to reach their target and will be briefly reviewed. Lastly, a most surprising recent observation is the presence of phosphorothioate groups in bacterial DNA where functions still remain to be fully determined.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25353652     DOI: 10.1089/nat.2014.0506

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  143 in total

1.  Synthetic CRISPR RNA-Cas9-guided genome editing in human cells.

Authors:  Meghdad Rahdar; Moira A McMahon; Thazha P Prakash; Eric E Swayze; C Frank Bennett; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

Review 2.  The Toolbox for Modified Aptamers.

Authors:  Sergey A Lapa; Alexander V Chudinov; Edward N Timofeev
Journal:  Mol Biotechnol       Date:  2016-02       Impact factor: 2.695

3.  The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma.

Authors:  Hon-Kit Andus Wong; Rachid El Fatimy; Courtney Onodera; Zhiyun Wei; Ming Yi; Athul Mohan; Sindhuja Gowrisankaran; Priya Karmali; Eric Marcusson; Hiroaki Wakimoto; Robert Stephens; Erik J Uhlmann; Jun S Song; Bakhos Tannous; Anna M Krichevsky
Journal:  Mol Ther       Date:  2015-04-23       Impact factor: 11.454

4.  Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells.

Authors:  Moira A McMahon; Thazha P Prakash; Don W Cleveland; C Frank Bennett; Meghdad Rahdar
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

5.  Application of Nucleic Acid Mimics in Fluorescence In Situ Hybridization.

Authors:  Ricardo Oliveira; Andreia S Azevedo; Luzia Mendes
Journal:  Methods Mol Biol       Date:  2021

Review 6.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 7.  Selective tissue targeting of synthetic nucleic acid drugs.

Authors:  Punit P Seth; Michael Tanowitz; C Frank Bennett
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

Review 8.  Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Authors:  Colton M Miller; Michael Tanowitz; Aaron J Donner; Thazha P Prakash; Eric E Swayze; Edward N Harris; Punit P Seth
Journal:  Nucleic Acid Ther       Date:  2018-02-09       Impact factor: 5.486

9.  Stereospecific Effects of Oxygen-to-Sulfur Substitution in DNA Phosphate on Ion Pair Dynamics and Protein-DNA Affinity.

Authors:  Dan Nguyen; Levani Zandarashvili; Mark A White; Junji Iwahara
Journal:  Chembiochem       Date:  2016-07-13       Impact factor: 3.164

Review 10.  Advances in therapeutic bacterial antisense biotechnology.

Authors:  John P Hegarty; David B Stewart
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-05       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.